At level 2, one patient exhibited grade 3 ileus on day 20 of the first cycle, but no other DLT occurred in phase I. The MTD was not reached, and we determined that the level 3 dosage was the RD, which was a CPT-11 dose of 150 mg m−2 with an S-1 dose of 80 mg m−2. This evidence concerns the gene PSMD1 and ileus.